Phathom Pharmaceuticals Announces FDA Acceptance for Filing of Vonoprazan NDA for the Treatment of Erosive Esophagitis
25 mai 2022 08h00 HE
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., May 25, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
Phathom Pharmaceuticals Submits Vonoprazan NDA to FDA for the Treatment of Erosive Esophagitis
14 mars 2022 08h02 HE
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., March 14, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
ROSEN, A LEADING NATIONAL FIRM, Encourages Fennec Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – FENC
22 févr. 2022 19h30 HE
|
The Rosen Law Firm PA
NEW YORK, Feb. 22, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) between May 28,...
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Reata Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – RETA
09 févr. 2022 17h15 HE
|
The Rosen Law Firm PA
NEW YORK, Feb. 09, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between...
Phathom Pharmaceuticals Reports Third Quarter 2021 Results and Provides Key Clinical, Regulatory, and Business Updates
08 nov. 2021 08h00 HE
|
Phathom Pharmaceuticals
Two New Drug Applications (NDAs) for vonoprazan-based treatment regimens for H. pylori infection were accepted for filing by FDA with six-month Priority Review granted; PDUFA target action date of May...
ARDX FINAL DEADLINE TUESDAY: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Ardelyx, Inc. Investors with Losses to Secure Counsel Before Important September 28 Deadline in Securities Class Action – ARDX
26 sept. 2021 15h15 HE
|
The Rosen Law Firm PA
NEW YORK, Sept. 26, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ardelyx, Inc. (NASDAQ: ARDX) between August 6, 2020 and...
Orphalan announces FDA acceptance for filing of New Drug Application (NDA) for trientine tetrahydrochloride (TETA 4HCl) for the treatment of Wilson’s Disease
02 sept. 2021 02h00 HE
|
Orphalan
Orphalan announces FDA acceptance for filing of New Drug Application (NDA) for trientine tetrahydrochloride (TETA 4HCl) for the treatment of Wilson’s Disease —NDA supported by positive data from...
ARDX INVESTOR NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Ardelyx, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ARDX
19 août 2021 16h15 HE
|
The Rosen Law Firm PA
NEW YORK, Aug. 19, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ardelyx, Inc. (NASDAQ: ARDX) between August 6, 2020 and...
ITRM NOTICE: ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED LAW FIRM, Encourages Iterum Therapeutics plc Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ITRM
19 août 2021 14h15 HE
|
The Rosen Law Firm PA
NEW YORK, Aug. 19, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Iterum Therapeutics plc (NASDAQ: ITRM) between November...
ARDX INVESTOR NEWS: ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – ARDX
13 août 2021 18h15 HE
|
The Rosen Law Firm PA
NEW YORK, Aug. 13, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ardelyx, Inc. (NASDAQ: ARDX) between August 6, 2020 and...